Dayton Therapeutics

In 2020, the E3 Life team established Dayton Therapeutics to acquire the late-stage developmental prostate cancer pharmaceutical, Satraplatin. We re-developed it for use against rare lymphomas.

Based on in-vitro lab research studies, we identified novel molecular mechanisms and biomarkers (published in a peer-reviewed journal) and filed for patents. Satraplatin’s molecular and clinical signature allowed us to identify primary CNS lymphoma (PCNSL) as the most suitable target indication, for which we established an appropriate clinical, regulatory, and manufacturing pathway.

In 2024, Satraplatin was successfully sold to a rapidly growing European specialty pharmaceutical company.